Buy Rating for Longeveron: ELPIS II Trial Progress and Financial Stability Highlighted

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Longeveron (LGVN – Research Report), retaining the price target of $10.00.

Ram Selvaraju has given his Buy rating due to a combination of factors including the imminent completion of enrollment for the ELPIS II trial, which is a pivotal Phase 2b study evaluating laromestrocel in hypoplastic left heart syndrome (HLHS). The trial’s potential to yield positive results could lead to a Biologics License Application (BLA) filing by the second half of 2026. The drug has received Orphan Drug, Fast Track, and Rare Pediatric Disease designations, which may expedite the review process.
Financially, Longeveron ended the first quarter of 2025 with $14.3 million in cash, expected to support operations into late 2025. The company’s net loss per share was in line with expectations, and the valuation model, based on discounted cash flow, suggests a firm value of $240 million. The probability of approval for Lomecel-B in HLHS is estimated at 60%, with a price target of $10 per share. However, risks include potential trial failures, regulatory hurdles, and competitive pressures.

In another report released on May 12, Maxim Group also maintained a Buy rating on the stock with a $6.00 price target.

Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LGVN in relation to earlier this year.